Metric characteristics of the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS): A practical combined rating scale for drug-induced movement disorders

Movement Disorders

Volumn 17, Issue 6, 2002, Pages 1354-1359

  Kim, Jong Hoon ^a,b,c   Jung, Hee Yeon ^a,d   Kang, Ung Gu ^a,b,c   Jeong, Seong Hoon ^a,b,c   Ahn, Yong Min ^e   Byun, Hee Jung ^f   Ha, Kyoo Seob ^a,b,c   Kim, Yong Sik ^a,b,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Seoul National University Boramae Hospital   (South Korea)

^e Eulji University School of Medicine   (South Korea)

^f Yong in Mental Hospital   (South Korea)

Author keywords

Akathisia; DIEPSS; Parkinsonism; Reliability; Tardive dyskinesia; Validity

Indexed keywords

ANTIPARKINSON AGENT; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; EMONAPRIDE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; SULPIRIDE; ZOTEPINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METRIC SYSTEM; PRIORITY JOURNAL; RATING SCALE; RELIABILITY; SCHIZOPHRENIA; SCORING SYSTEM; VALIDATION PROCESS;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; OBSERVER VARIATION; PARKINSONIAN DISORDERS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA;

EID: 0036868951     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10255     Document Type: Article

References (30)

1. Barnes TR, Kane JM. The assessment of movement disorder in psychosis. In: Barnes TR, Nelson HE, editors. The assessment of psychoses. London: Chapman and Hall Medical; 1994. p 191-210.
2. Conley RR. Evaluating clinical trial data: outcome measures. J Clin Psychiatry 2001;62(Suppl. 9):23-26.
3. Barnes TR, McPhillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry 1999;174(Suppl. 38):34-43.
4. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000;61(Suppl. 3):16-21.
5. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
6. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
7. Guy W. ECDEU assessment manual for psychopharmacology. Bethesda, MD: U.S. Department of Health, Education, and Welfare; 1976.
8. Owens DGC. A guide to the extrapyramidal side-effects of anti-psychotic drugs. Cambridge: Cambridge University Press; 1999.
9. Gerlach J, Korsgaard S, Clemmesen P, Lauersen AM, Magelund G, Noring U, Povlsen UJ, Bech P, Casey DE. The St. Hans rating scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand 1993;87:244-252.
10. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. Extrapyramidal rating scale. Can J Neurol Sci 1980;7:233.
11. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 1994;9:76-83.
12. Rabey JM, Bass H, Bonuccelli U, Brooks D, Klotz P, Korczyn AD, Kraus P, Martinez-Martin P, Morrish P, Van Sauten W, Van Hilten B. Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol 1997;20:322-337.
13. Inada T. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to its usage. Tokyo: Seiwa Shoten Publishers; 1996.
14. Kim JH, Lee BC, Park HJ, Ahn YM, Kang UG, Kim YS. Subjective emotional experience and cognitive impairment in drug-induced akathisia. Compr Psychiatry 2002 (in press).
15. Inada T, Yagi G. Current topics in tardive dyskinesia in Japan. Psychiatry Clin Neurosci 1995;49:239-244.
16. Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. Psychiatry Clin Neurosci 2001;55:403-414.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Press; 1994.
18. Rey MJ, Schulz P, Costa C, Dick P, Tissot R. Guidelines for the dosage of neuroleptics. I. Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol 1989;4:95-104.
19. Meyer JM, Simpson GM. Anticholinergics and amantadine. In: Sadock BJ, Sadock VA, editors. Comprehensive textbook of psychiatry, 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2000. p 2276-2282.
20. Ballenger JC. Benzodiazepine receptor agonists and antagonists. In: Sadock BJ, Sadock VA, editors. Comprehensive textbook of psychiatry, 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2000. p 2317-2324.
21. Giraudeau B, Mary JY. Planning a reproducibility study: how many subjects and how many replicates per subject for an expected width of the 95% confidence interval of the intraclass correlation coefficient. Stat Med 2001;20:3205-3214.
22. Hair JF Jr, Anderson RE, Tatham RL, Black WC. Multivariate data analysis, 5th ed. New Jersey: Prentice-Hall International; 1998.
23. Murphy JM, Berwick DM, Weinstein MC, Borus JF, Budman SH, Klerman GL. Performance of screening and diagnostic tests. Application of receiver operating characteristic analysis. Arch Gen Psychiatry 1987;44:550-555.
24. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994; 51:963-974.
25. Cassady SL, Thaker GK, Summerfelt A, Tamminga CA. The Maryland Psychiatric Research Center scale and the characterization of involuntary movements. Psychiatry Res 1997;70:21-37.
26. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487.
27. Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32:1335-1346.
28. Muscettola G, Barbato G, Pampallona S, Casiello M, Bollini P. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 1999;19:203-208.
29. Van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS. The inter-relationships of tardive dyskinesia, Parkinsonism, akathisia, and tardive dystonia: the Curacao Extrapyramidal Syndromes Study II. Schizophr Res 1997;26:235-242.
30. Loonen AJ, Doorschot CH, van Hemert DA, Oostelbos MC, Sijben AE. The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity. Int J Neuropsychopharmacol 2000;3:285-296.